Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - July 05.11.2026 FJUL.LN IE000YJBT6I5 150,002.00 USD 4,294,050.12 28.627 ...
-
NATIXIS UK Regulatory Announcement: Form 8.3 Gamma communications plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
NATIXIS UK Regulatory Announcement: Form 8.3 Bodycote plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - October 05.11.2026 FOCT.LN IE0004X8KUG5 100,002.00 USD 2,968,047.97 29.680 ...
-
Endesa, S.A. UK Regulatory Announcement: Treasury Stock
MADRID--(BUSINESS WIRE)-- Borja Acha Besga Secretary of the Board of Directors Madrid, 6 November 2026 Other relevant information In accordance with the provisions of Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Endesa, S.A. ('Endesa' or 'the Company') hereby discloses the following information: Further to the capital reduction announced on 29 September 2026 through an Other Relevant Information communication (registration number 42928), it is hereby i...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 05.11.2026 FJAN.LN IE000MDKBOB3 150,002.00 USD 4,353,205.62 29.021 ...
-
Informa TechTarget Reports Third Quarter 2026 Results
NEWTON, Mass.--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT), (“Informa TechTarget” or the “Company”), an indispensable partner for B2B intelligence, media and marketing solutions, reports financial results for the third quarter ended September 30, 2026. Gary Nugent, Chief Executive Officer, Informa TechTarget, said: “We are operating with discipline in a market that continues to be shaped by macro volatility and AI investment. We continue to strengthen our product offering and sharpen our g...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Capital Strength UCITS ETF 05.11.2026 FTCS. IE00BL0L0D23 200,002.00 USD 7,251,280.58 36.256 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 05.11.2026 FVD. IE00BKVKW020 200,002.00 USD 6,342,042.08 31.710 ...
-
BeOne Medicines公布2026年第三季財務業績及業務更新
加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235)今天公布了2026年第三季的財務業績和公司最新進展。 BeOne共同創辦人、董事長兼執行長John V. Oyler表示: 「我們強勁的第三季業績和上調的全年指引反映了我們在全球血液學領域的持續快速成長和領先地位,這主要歸功於我們的基礎性BTK抑制劑BRUKINSA,該藥物能夠為病患帶來強效且持久的療效。如今,我們又推出了下一代BCL2抑制劑BEQALZI。我們期待在未來幾個月迎來腫瘤領域最深厚研發產品線之一(涵蓋血液學和實質腫瘤)的多項利好因素,並憑藉我們在研發、生產和商業化方面的差異化能力加快推進。」 (金額以千美元為單位,未經稽核) 截至以下日期的三個月 截至以下日期的九個月 9月30日 9月30日 2026年 2025年 變化百分比 2026年 2025年 變化百分比 產品淨營收 $...